The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS).
 
Joanna Vitfell-Rasmussen
Stock and Other Ownership Interests - Novo Nordisk (I)
Travel, Accommodations, Expenses - Novartis
 
Maja Lind-Hansen
No Relationships to Disclose
 
Akmal Safwat
No Relationships to Disclose
 
Philip Rossen
No Relationships to Disclose
 
Poul Knoblauch
Employment - Onxeo
Stock and Other Ownership Interests - Onxeo
 
Robin L Jones
Research Funding - Bayer; Eisai; GlaxoSmithKline; ImClone Systems; Johnson & Johnson; Morphotek; Novartis; Threshold Pharmaceuticals
 
Ian Robert Judson
Honoraria - GlaxoSmithKline; Merck Serono; PharmaMar
Consulting or Advisory Role - Bayer Schering Pharma; GlaxoSmithKline
Research Funding - Eisai (Inst); GlaxoSmithKline (Inst); Novartis (Inst); PharmaMar (Inst)
 
Anders Krarup-Hansen
No Relationships to Disclose